triazolam has been researched along with Sensation Disorders in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
Sensation Disorders: Disorders of the special senses (i.e., VISION; HEARING; TASTE; and SMELL) or somatosensory system (i.e., afferent components of the PERIPHERAL NERVOUS SYSTEM).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Robin, DW | 1 |
| Hasan, SS | 1 |
| Edeki, T | 1 |
| Lichtenstein, MJ | 1 |
| Shiavi, RG | 1 |
| Wood, AJ | 1 |
1 trial available for triazolam and Sensation Disorders
| Article | Year |
|---|---|
Increased baseline sway contributes to increased losses of balance in older people following triazolam.
Topics: Adult; Age Factors; Aged; Aging; Double-Blind Method; Drug Monitoring; Humans; Hypnotics and Sedativ | 1996 |